Results 11 to 20 of about 11,256 (207)

Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance. [PDF]

Trends in Molecular Medicine, 2021
Histone eviction and chromatin relaxation are important processes for efficient DNA repair. Poly(ADP) ribose (PAR) polymerase 1 (PARP1) is a key mediator of this process, and disruption of PARP1 activity has a direct impact on chromatin structure.
Andronikou, Christina, Rottenberg, Sven, Christina Andronikou, Sven Rottenberg   +3 more
core   +5 more sources

Fully Automated, High-Dose Radiosynthesis of [(18)F]PARPi [PDF]

Pharmaceuticals, 2022
[(18)F]PARPi is currently undergoing clinical trials as a PET tracer for many applications. However, only manual radiosynthesis was reported; this has several drawbacks, including an increased risk of contamination from the operator, and the need to ...
Herrmann, Ken, Michael Nader, Pacelli, Anna, Fendler, Wolfgang P., Anna Pacelli, Thibault Gendron, Wolfgang Fendler, Nader, Michael, Wolfgang P. Fendler, Fadi Zarrad, Alex Jackson, Ken Herrmann, Charles Vriamont, Zarrad, Fadi, Corentin Warnier, Muhammad Otabashi   +15 more
core   +7 more sources

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy

Cancer Drug Resistance, 2022
Epithelial ovarian cancer remains the most lethal female malignancy despite options for systemic therapy and the emergence of targeted therapies. Although initial response to therapy is observed, recurrence and ultimately chemoresistance result in ...
Summey, Rebekah, Uyar, Denise
core   +3 more sources

Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma

Journal of Cellular and Molecular Medicine
Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal disease with limited treatment options. PARP inhibitors (PARPi) have shown promise in treating PDAC with homologous recombination deficiency (HRD), but rapid acquisition of resistance limits their
Lowery, Maeve A., Stoof, Jojanneke, Andrieu, Charlotte, O'Sullivan, Jacintha, Lowery, Maeve A, O'Connell, Fiona, Walsh, Naomi   +6 more
core   +4 more sources

Vitamin C Enhances PARPi Efficacy for the Treatment of AML

Blood, 2021
Poly-ADP-ribose polymerase inhibitors (PARPi) are currently in clinical trial to determine their therapeutic efficacy for the treatment of acute myeloid leukemia (AML).
Strippoli, Victoria, Fang, Byron, Verdun, Ramiro E, Cimmino, Luisa, Chaudhry, Sana, Bilbao, Daniel, Bañuelos, Carolina, Mohammad, Sofia, Yap, Yoon-Sing, Nimer, Stephen, Leesang, Tiffany, Lam, Minh, Brabson, John P, Lyon, Peter, Neel, Benjamin G, Wang, Jingjing, Figueroa, Maria E., Byron Fang, Peter Lyon, Luisa Cimmino, Victoria Strippoli, Maria E. Figueroa, Tiffany Leesang, Stephen Nimer, Sofia Mohammad, Benjamin G Neel, John P Brabson, Jingjing Wang, Minh Lam, Carolina Bañuelos, Daniel Bilbao, Sana Chaudhry, Yoon-Sing Yap, Ramiro E Verdun   +33 more
core   +2 more sources

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging

Neoplasia, 2014
New intravital optical imaging technologies have revolutionized our understanding of mammalian biology and continue to evolve rapidly. However, there are only a limited number of imaging probes available to date.
Christian Brand, Thomas Reiner, Yachao Zhang, Christopher P. Irwin, Wolfgang A. Weber, Yasiri Portorreal, Beatriz Salinas, Pooja Desai   +7 more
core   +4 more sources

PARPi, BRCA, and gaps: controversies and future research. [PDF]

Trends in Cancer
In recent years, various poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been approved for the treatment of several cancers to target the vulnerability of homologous recombination (HR) deficiency (e.g., due to BRCA1/2 dysfunction).
Widmer, Carmen A, Rottenberg, Sven, Dibitetto, Diego   +2 more
core   +4 more sources

Sensitivity of Platinum-Based Chemotherapy and Efficacy of Arsenic Trioxide-Based Non-Platinum Chemotherapy Following the Progression of PARPi Maintenance Therapy: A Real-World Study

Cancer Medicine
Background Cross‐resistance is observed between platinum and Poly (ADP‐ribose) polymerase inhibitors (PARPi). We aim to propose the definition of PARPi resistance and demonstrate the best therapeutic strategy for patients with PARPi resistance. Methods A
Rui Gou, Xiaoyan Shen
exaly   +2 more sources

First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis [PDF]

Journal of Immunotherapy and Precision Oncology, 2021
Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) 1 and 2, has been shown to improve progression free survival in patients when used as maintenance treatment after first-line platinum-based chemotherapy in advanced stage (III to IV ...
Alistair McLaren, Douglas Cartwright, Ewen Ross, Patricia Roxburgh   +3 more
doaj   +1 more source

Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer

Frontiers in Oncology
ObjectiveThe current clinical data regarding the re-administration of PARPi maintenance therapy in platinum sensitive recurrent ovarian cancer (PSROC) is limited.
Yulin Wang, Yunjie Yang, Binghong Guo, Binghong Guo, Xiaoyan Li, Renakezi Tuersun, Ye Cao, Jundong Li, Jihong Liu, Su Li, Tao Liu, Yongwen Huang   +11 more
doaj   +3 more sources